Fosamax Osteonecrosis of the Jaw Settlement: Criteria Explained

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Specific Pharmaceutical Risks

The legacy context of general health and science information has long provided the public with accessible guidance on maintaining well-being, including during periods of societal disruption such as the COVID-19 pandemic. Within this framework, discussions have often centered on lifestyle factors, such as alcohol consumption patterns, and their potential to influence physical and psychological health. This broad foundation, which emphasizes awareness of how daily habits intersect with long-term health outcomes, naturally extends to more specific considerations regarding pharmaceutical exposures and their associated risks. Transitioning from this general health perspective, the focus now shifts to a particular occupational exposure concern. In mass production environments, workers may encounter materials or substances that carry distinct health implications. One such area of inquiry involves the use of bisphosphonate medications, like Fosamax, which are prescribed for bone-related conditions. For individuals in manufacturing or industrial settings, understanding the criteria for settlements related to Fosamax and osteonecrosis of the jaw becomes relevant. This pivot from general health literacy to a targeted occupational concern underscores the importance of recognizing how specific exposures in the workplace can lead to distinct legal and medical considerations, without delving into mechanistic claims or citing external evidence.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication prescribed to treat osteoporosis. A known adverse effect associated with its use is osteonecrosis of the jaw (ONJ), a condition involving bone death in the jaw that can lead to pain, infection, and tooth loss. Understanding the clinical presentation, risk factors, and settlement criteria for affected patients requires a careful review of the available evidence. Osteonecrosis of the jaw is characterized by exposed bone in the oral cavity that does not heal within eight weeks. The condition can occur spontaneously but is generally associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The time to onset of symptoms after starting Fosamax varies widely, from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, though a subset may have recurrence of symptoms if rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Pharmacology and Mechanistic Insights

Fosamax (alendronate) works by inhibiting bone resorption, which helps increase bone density in osteoporosis patients. However, its effect on bone turnover may contribute to ONJ development. Research using animal models has provided insights into jawbone-specific responses to bisphosphonate therapy. A multiscale characterization of jawbone in estrogen-deficient rats treated with alendronate found that most jawbone characteristics in ovariectomized (OVX) and treatment groups were not significantly different from those of the sham group (https://pubmed.ncbi.nlm.nih.gov/40345077/). The surface of alveolar bone surrounding teeth showed a trend of more erosion and addition of new bone tissues in the OVX rat groups compared to the sham group (https://pubmed.ncbi.nlm.nih.gov/40345077/). All tissue mineral density parameters rapidly increased up to 60 μm from the periodontal ligament surrounding teeth regardless of the treatment groups (https://pubmed.ncbi.nlm.nih.gov/40345077/). Treatments using each therapeutic agent and its combination did not substantially change those characteristics of jawbones in OVX rats (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings are different from those of lumbar vertebrae in the same rats that showed significant bone alteration by OVX and treatments (https://pubmed.ncbi.nlm.nih.gov/40345077/). This multiscale characterization provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Risk Factors and Adequacy of Warnings

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings regarding Fosamax and ONJ is a key consideration. The prescribing information for Fosamax includes a specific warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Similarly, the label for Fosamax Plus D includes a detailed warning about ONJ, listing known risk factors and noting that the risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide information to healthcare providers and patients about the potential risk.

Settlement Criteria for Affected Patients

For patients who have developed ONJ after using Fosamax, settlement criteria typically consider several factors. The timeline between exposure to Fosamax and documented harm is important, as the time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients must demonstrate that they used Fosamax and subsequently developed ONJ, and that other known risk factors (such as invasive dental procedures or cancer therapies) were not the primary cause. The presence of other risk factors, such as poor oral hygiene or co-morbid disorders, may affect the assessment of whether the harm was primarily due to Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Additionally, the duration of Fosamax use is relevant, as the risk of ONJ may increase with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific case based on these criteria.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis. A known adverse effect is osteonecrosis of the jaw (ONJ), a condition where bone tissue in the jaw dies, leading to pain, infection, and tooth loss. The risk is documented in prescribing information and may increase with longer use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the settlement criteria for Fosamax-related ONJ?

Settlement criteria typically require documented use of Fosamax, a confirmed ONJ diagnosis, and evidence that other risk factors (e.g., invasive dental procedures, cancer therapies) were not the primary cause. The timeline from exposure to harm and duration of use are also considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.